Ras-related protein R-Ras2 (RRAS2)

Ras-related protein R-Ras2 (RRAS2) is a member of the R-Ras subfamily of small GTPases within the RAS superfamily, functioning as an intracellular signal transducer involved in pivotal cellular processes including proliferation, survival, migration, and immune signaling[1][2][3][4][6]. The protein localizes to the plasma membrane and to focal adhesions, and through its GTPase activity, it regulates downstream pathways such as PI3K-AKT and MAPK/ERK, driving cellular growth and differentiation[1][4][6]. Oncogenic mutations in RRAS2 (e.g., G23V, Q72L) cause hyperactivation of these pathways and are implicated in a variety of cancers (breast, leukemias, rhabdomyosarcoma) as well as Noonan syndrome type 12 (NS12), a developmental disorder classified under RASopathies[2][3][4]. RRAS2 also mediates important immune cell functions, particularly in B and T lymphocytes[1][4]. While no drugs currently target RRAS2 directly in the clinic, its interaction with PI3Kα and downstream pathway effectors makes it a candidate for future therapeutic intervention[1][4][6].

Other names

TC21Teratocarcinoma oncogeneNS12Ras-like protein TC21Related RAS viral (r-ras) oncogene homolog 2RRAS2 (official gene/protein symbol)

Potential mechanisms for drugs targeting this molecule include: Inhibition of GTPase activity (potential but not clinically available); Disruption of RRAS2-PI3Kα binding; Downregulation of RAS pathway signaling (by targeting downstream effectors like PI3K, RAF, MEK, or ERK).